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Background: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive.
Data suggest risk associations vary by tumour characteristics.
Methods: We conducted a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC)
to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n¼ 565 cases). Multivariable conditional logistic
regression models were used to estimate associations.
Results: We observed no association between IGF-I and EOC overall or by tumour characteristics.
Conclusions: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum
IGF-I concentrations may not influence EOC risk.
Insulin-like growth factor I (IGF-I)-related signalling pathways are
implicated in the aetiology of epithelial cancer at various sites (e.g.,
prostate, colon and breast cancer), including ovarian cancer
(reviewed in Bruchim and Werner, 2013; Singh et al, 2014).
Insulin-like growth factor I drives cellular proliferation in several
cell lines of epithelial neoplasms (reviewed in Pollak, 2008) and is
additionally associated with invasion and angiogenesis in epithelial
ovarian cancer cells (reviewed in Beauchamp et al, 2010). Recently,
IGF-I was shown to be overexpressed in low-grade, but not high-
grade, serous ovarian cancer cell lines, suggesting IGF-I may be
differentially associated with risk across ovarian cancer subtypes
(King et al, 2011). Further, low-grade ovarian cancer cells
expressing IGF-I were more responsive to IGF-I stimulation and
IGF-I receptor (IGF-IR) inhibition compared with high-grade
serous ovarian cancer cells (King et al, 2011).
Prior prospective studies on the association between pre-
diagnostic circulating IGF-I and epithelial invasive ovarian cancer
(EOC) were inconclusive and evaluated EOC as a single disease
entity, without addressing associations in EOC subgroups (i.e.,
histologic subtype, dualistic model of ovarian carcinogenesis)
(Lukanova et al, 2002; Peeters et al, 2007; Tworoger et al, 2007).
This is the largest prospective study to date (n¼ 565 cases; 1097
controls) investigating the role of IGF-I and EOC risk, and the first
prospective investigation to assess IGF-I and EOC by tumour
characteristics (histology, grade, stage and type I/II status).
MATERIALS AND METHODS
Study population. The European Prospective Investigation into
Cancer and Nutrition (EPIC) is an ongoing multicentre prospective
cohort study. Descriptions of study design, population and baseline
data collection of the cohort (Riboli et al, 2002) and this nested case–
control study (Ose et al, 2014) have been reported in detail. Briefly,
519 978 participants (366 521 women) aged 25–70 years were enrolled
from 1992 to 2000 in 10 European countries. Data on diet,
reproductive factors, use of exogenous hormones (oral contraceptives
(OC) and hormone replacement therapy (HRT)), disease history and
anthropometric measures were collected at baseline. A total of 226 673
women provided a baseline blood sample.
Women not using exogenous hormones at blood donation and
with no history of cancer at recruitment (with the exception of
non-melanoma skin cancer) were eligible for this study.
A total of 565 eligible cases with biological samples and incident
epithelial invasive ovarian, fallopian tube or primary peritoneal
cancer were 1:2 matched to 1097 controls. An incidence density
sampling protocol was used. We included 201 cases and 372
matched controls from a prior analysis in EPIC (phase 1; Peeters
et al, 2007) and additional 364 cases (725 matched controls)
subsequently diagnosed during follow-up (phase 2).
Information on tumour characteristics (histologic subtype (serous,
endometrioid, clear cell, mucinous and not otherwise specified
(NOS)), grade (well, moderately or poorly/undifferentiated) and stage
(local, regional and metastatic)) was available from pathology reports
and from cancer registries. Tumours were classified on the basis of
histology and the proposed dualistic pathway of ovarian carcinogen-
esis (type I/II; Kurman and Shih, 2011). Clear cell carcinomas
(n¼ 28) were excluded from type I/II analyses as they show unique
clinical behaviour (Penson et al, 2013). All participants gave written
informed consent. The Ethical Review Board of the International
Agency for Research on Cancer and the Institutional Review Board
of each EPIC centre approved these analyses.
Laboratory assays. Pre-diagnostic concentrations of IGF-I
(nmol l 1) were analysed with enzyme-linked immunosorbent
assays at IARC (phase 1 (Peeters et al, 2007): DSL, Webster, TX,
USA) and at the Division of Cancer Epidemiology at the German
Cancer Research Center (phase 2: Immunodiagnostics Systems,
Frankfurt, Germany). Cases and matched controls were analysed
within the same analytical batch by laboratory technicians blinded
to case–control status and identity of quality control samples.
Intra- and inter-batch coefficients of variation from replicate
quality control (QC) samples were 2.50% and 12.20% (phase 1:
triplicate QCs), and 9.42% and 8.93% (phase 2: duplicate QCs).
Statistical analyses. Insulin-like growth factor I values were log2
transformed and centred to a mean value of zero in each phase.
Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated using conditional logistic regression. Insulin-like growth
factor I was examined continuously on the log2 scale and in tertiles
with phase-specific cut-offs based on the distribution in controls.
The final model included full-term pregnancy (never/ever), as
other covariates (BMI, height, smoking, physical activity, diabetes,
alcohol, age at menarche, age at first birth, number of births, age at
menopause, OC use and HRT use) did not change the OR by
410% (i.e., by a factor 1.10 or its reciprocal; Maldonado and
Greenland, 1993).
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Heterogeneity in the associations between IGF-I and EOC by
tumour characteristics was assessed using likelihood ratio tests
comparing logistic regression models with and without corre-
sponding interaction terms (Rothman et al, 2008).
Sensitivity analyses included stratification by menopausal status
at blood donation and age at diagnosis (o55 and X55 years);
exclusion of women providing a blood sample o2 years before
diagnosis (to ensure any observed associations were not due to
cancers influencing circulating concentrations of IGF-I, but not yet
diagnosed) and women who had a prior hysterectomy.
All statistical tests were two-tailed and significant at the Po0.05
level. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was used for all
statistical analysis.
RESULTS
Cases and controls were similar with respect to most characteristics,
except for established reproductive risk factors (e.g., cases were less
likely to be parous, Po0.01 or to use OCs, Po0.01; Table 1). We
observed no case–control differences in IGF-I concentrations overall
or by study phase.
There was no association between EOC and IGF-I concentra-
tions for doubling of hormone concentrations or comparing top to
bottom tertiles in overall analyses (all histological subtypes
combined (ORlog2¼ 0.88; 95% CI 0.71–1.08)). A similar pattern
was observed in subgroup analyses by tumour characteristics (e.g.,
serous tumours: ORlog2¼ 0.98; 95% CI 0.74–1.30; Table 2). We did
not observe heterogeneity between risk associations by tumour
characteristics (e.g., Phet for histological subtypes¼ 0.12). Overall,
risk estimates were similar when analyses were restricted to study
phase 2 (data not shown).
Results were similar in sensitivity analyses by age at diagnosis
(o55 vs X55) and menopausal status at blood donation (pre- vs
postmenopausal at blood donation). Excluding women with
unilateral oophorectomy/hysterectomy (n¼ 116) or women diag-
nosed within 2 years after blood donation (n¼ 84) led to results
comparable to overall results (data not shown).
DISCUSSION
This is the largest prospective study on the relationship between
IGF-I and EOC to date and the first to assess risk associations by
tumour characteristics. We observed no association between IGF-I
and EOC overall. The same pattern was observed in analyses
stratified by tumour characteristics, age at diagnosis or menopausal
status at blood donation.
Three prospective studies (range: 132 cases (Lukanova et al,
2002) to 222 cases (Tworoger et al, 2007)) have evaluated this
association previously. Two of these studies observed a positive
association between IGF-I and EOC in women o55 at diagnosis
(Lukanova et al, 2002; Peeters et al, 2007); however, sample size in
these subgroups was limited (np66 younger than 55 at diagnosis)
and confidence intervals were wide (i.e., ORQ3-Q1¼ 5.10; 95%
CI 1.50–18.20 (Peeters et al, 2007)). In a US-based study, no
association was observed in women diagnosed before the age of 55,
but there was an inverse association in women diagnosed after the
age of 55 (ORQ4-Q1¼ 0.52; 95% CI 0.28–0.95 (Tworoger et al,
2007)). Slightly different exclusion criteria might contribute to
inconsistent results across studies (e.g., exclusion of: cases
diagnosed within 1 year after blood donation (Lukanova et al,
2002), fallopian tube cancers (Tworoger et al, 2007), unilateral
oophorectomy/hysterectomy (EPIC phase 1; Peeters et al, 2007). In
the current study including 565 EOC cases, we observed no
association between IGF-I and ovarian cancer risk regardless of the
age at diagnosis.
Elevated IGF-I concentrations may lead to the development of a
malignant cell rather than to apoptotic cell death in the early
phases of carcinogenesis (reviewed in Pollak, 2008). Insulin-like
growth factor I signalling is predominantly mediated by the
IGF-IR; higher IGF-IR expression is associated with development
of epithelial neoplasms through anti-apoptotic and mitogenic
Table 1. Selected baseline characteristics of EOC cases and
matched controls at enrolment in the EPIC study
Cases
(n¼565)a
Controls
(n¼1097)a P-valueb
Age at blood donationc 57.0 (33.6–80.7) 56.9 (33.6–79.3)
Age at diagnosis 63.6 (37.4–86.5)
Lag time between blood
donation and diagnosis
6.7 (0–16)
Menopausal status at blood donationb
Pre 112 (20%) 219 (20%)
Post 453 (80%) 878 (80%)
Age at menopaused 50 (32–60) 50 (30–59) 0.03
Ever full-term pregnancy o0.01
No 95 (17%) 124 (12%)
Yes 448 (83%) 935 (88%)
OC use o 0.01
Never 349 (62%) 594 (54%)
Ever 214 (38%) 498 (46%)
HRT useb 0.57
Never 452 (87%) 867 (86%)
Ever 69 (13%) 145 (14%)
Histology
Serous 302 (53%)
Mucinous 41 (7%)
Endometrioid 66 (12%)
Clear Cell 28 (5%)
NOS 99 (18%)
Other 29 (5%)
Gradee,f
Low grade 35 (10%)
High grade 308 (90%)
Stagee,g
Low stage 76 (15%)
High stage 420 (85%)
Type I/IIe
Type I 67 (22%)
Type II 242 (78%)
IGF-I (nmol l 1) h 13.98 (13.39–14.6) 14.06 (13.63–14.5) 0.26
Abbreviations: EOC¼ epithelial ovarian cancer; EPIC¼European Prospective Investigation
into Cancer and Nutrition; HRT¼ hormone replacement therapy; IGF-I¼ insulin-like growth
factor I. Values are shown as median (range) or number (percentage).
aCases and controls in both study phases were matched on: study recruitment centre, age
at blood donation (±6 months), time of the day of blood collection (±1 h), fasting status
(o3 h, 3–6 h, 46 h) and menopausal status at blood collection (premenopausal,
perimenopausal and postmenopausal), as well as menstrual cycle phase for premenopausal
women (‘early follicular’ (days 0–7 of the cycle), ‘late follicular’ (days 8–11), ‘peri-ovulatory’
(days 12–16), ‘mid-luteal’ (days 20–24) and ‘other luteal’ (days 17–19 or days 25–40 ). Cases
missing data on the phase of menstrual cycle were matched to controls with missing
information on menstrual cycle phase.
bAmong postmenopausal women only.
cMatching factor.
dDifferences between cases and matched controls based on conditional logistic regression.
ePercentages presented among women with data on tumour characteristics. Percentage of
missing data: grade (39%), stage (12%) and type I/II status (45%).
fLow-grade tumours: well differentiated tumours; high-grade tumours: moderately, poorly
or undifferentiated tumours.
gLow-stage tumours: localised tumours; high-grade tumours: regional metastatic or distant
metastatic tumours.
hDifferences in IGF-I concentrations between cases and matched controls based on
geometric mean (95% confidence interval); values from each study phase are standardised
to a mean of 0 for analyses.
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activities and its role in oncogenic transformation (reviewed in
Pollak, 2008). We hypothesised that circulating IGF-I would be
differentially associated with ovarian cancer subtypes given the
differential expression of IGF-I in low- and high-grade serous
tumours. Insulin-like growth factor I has been shown to be
overexpressed in low-grade serous ovarian cancer cell lines (i.e.,
type I), which were more responsive to IGF-I stimulation and IGF-
IR inhibition compared with high-grade serous ovarian cancer cell
lines (i.e., type II) (King et al, 2011). We did not observe the
hypothesised associations; however, we had small sample size in
some subgroups (i.e., low-grade serous tumours, n¼ 35).
Our study has important strengths and limitations. We
investigated pre-diagnostic serum IGF-I and EOC risk in a large,
well-characterised nested case–control study. However, circulating
IGF-I may not be reflective of IGF-I exposure in the ovary.
Although the data on this association are mixed (Rabinovici et al,
1990; Thierry van Dessel et al, 1996), there is evidence to suggest
that follicular fluid concentrations are well correlated with serum
concentrations (r¼ 0.77, Po0.001; Dorn et al, 2003). In addition,
the current analysis is based on a single biomarker in the IGF
signalling axis. However, data to date suggest IGF-I and the IGF-IR
are the most relevant members of the IGF family for ovarian
carcinogenesis (reviewed in Beauchamp et al, 2010). In line with
other epidemiologic studies, a single measurement was used to
evaluate risk associations. However, relatively high intra-individual
reproducibility of IGF-I measurements has been consistently
shown (2–3 years; premenopausal women: ICC¼ 0.86 (Missmer
et al, 2006), up to 5 years; pre- and postmenopausal women:
ICC¼ 0.71 (Borofsky et al, 2002)).
The sample size for subgroup analyses by tumour characteristics
(e.g., histology, grade or type I/type II) may have been too small to
detect an association, with the exception of the group of serous
tumours (cases n¼ 302). For subgroup analyses by grade as well as
type I/type II classification a considerable proportion of data was
missing (439%), further limiting sample size in those subgroups.
Despite evidence suggesting that IGF-I could be involved in
EOC development (reviewed in Bruchim and Werner, 2013; Singh
et al, 2014), our study shows no association between circulating
IGF-I and EOC risk. Larger, pooled prospective studies are needed
to confirm our results and to address the associations in small
subgroups with more statistical power and assess risk associations
with expression of IGF receptors.
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Table 2. OR (95% CI) for ovarian cancer by tertiles and for doubling of IGF-I by tumour characteristics and menopausal statusa
Tertilesb
1 2 3
ORlog2
(95% CI) Ptrend
c Phet
d
Overall 565 sets ref. 0.93 (0.72–1.20) 0.92 (0.70–1.20) 0.88 (0.71–1.08) 0.21
Histology
Serous 302 sets ref. 1.02 (0.72–1.46) 1.03 (0.71–1.48) 0.98 (0.74–1.30) 0.90
Mucinous 41 sets ref. 1.07 (0.42–2.73) 0.60 (0.20–1.82) 0.59 (0.24–1.42) 0.24
Endometrioid 66 sets ref. 1.01 (0.43–2.34) 0.93 (0.37–2.32) 0.73 (0.34–1.56) 0.42
Clear cell 28 sets ref. 1.52 (0.43–5.36) 0.99 (0.29–3.40) 0.89 (0.37–2.13) 0.80
NOS 99 sets ref. 0.63 (0.36–1.12) 0.67 (0.36–1.24) 0.75 (0.48–1.17) 0.21
Other 29 sets ref. 0.89 (0.28–2.78) 1.71 (0.42–6.87) 1.07 (0.40–2.83) 0.89 0.12
Grade
Low grade 35 sets ref. 0.24 (0.06–1.08) 0.56 (0.15–2.00) 0.87 (0.34–2.24) 0.78
High grade 306 sets ref. 0.95 (0.68–1.34) 1.01 (0.70–1.47) 0.96 (0.72–1.28) 0.79 0.89
Stage
Low stage 76 sets ref. 1.23 (0.57–2.67) 1.39 (0.65–3.01) 1.02 (0.56–1.85) 0.95
High stage 419 sets ref. 0.98 (0.73–1.31) 0.87 (0.64–1.19) 0.86 (0.68–1.09) 0.21 0.52
Type I/II
Type I 67 sets ref. 0.69 (0.31–1.54) 0.72 (0.32–1.62) 0.84 (0.43–1.64) 0.61
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X55 years 459 sets ref. 1.04 (0.79–1.36) 0.95 (0.71–1.28) 0.87 (0.70–1.09) 0.23 0.83
Abbreviations: CI¼ confidence interval; IGF-I¼ insulin-like growth factor I; OR¼odds ratio.
aMatched for study centre, age at blood donation, menopausal status, time of day of blood collection, fasting status and phase of the menstrual cycle and additionally adjusted for ever full-
term pregnancy (never/ever).
bPhase-specific cut-offs; raw data IGF-I (nmol l 1) for phase 1: first tertile 16.30–23.61; second tertile 23.62–33.95; third tertile:433.95. Phase 2: first tertile 8.05–10.95; second tertile 10.96–15.10;
third tertile 415.10.
cLinear trends for OR estimated on log2 continuous scale.
dStatistical tests for heterogeneity were based on likelihood ratio test, comparing the model fit for logistic regression models with and without corresponding interaction term.
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